Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia
- Conditions
- Acute Lymphoblastic LeukemiaJuvenile Myelomonocytic LeukemiaAcute Myeloblastic Leukemia
- Interventions
- Other: Yttrium-90 labelled monoclonal antibody against CD66
- Registration Number
- NCT04082286
- Brief Summary
The radio-labeled anti-CD66 monoclonal antibody (with 111In for dosimetry and 90Y for therapy) will be administered in the T11 North room, UCLH, while the reduced intensity conditioning regimen and the allogeneic hematopoietic stem cell transplant will be performed in 2 centers, according to the age of the patient: A) patients aged \< 13 years will be transplanted at the Bone Marrow Transplantation Department, Great Ormond Street Hospital (GOSH), and B) patients aged 13-18 years will be transplanted at the Bone Marrow Transplantation Department, University College London Hospitals (UCLH).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Radioimmunotherapy Yttrium-90 labelled monoclonal antibody against CD66 Children affected by high risk malignant disorders will be receiving increasing infused activity of a radio-immune conjugated antibody as part of their conditioning regimen prior to alleogeneic stem cell transplantation
- Primary Outcome Measures
Name Time Method maximum tolerated dose (MTD) 45 days post transplant targeted radiotherapy delivered by 90Yttrium-labelled anti-CD66
dose limited toxicity (DLT) 45 days post transplant targeted radiotherapy delivered by 90Yttrium-labelled anti-CD66
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Great Ormond Street Hospital for Children
🇬🇧London, United Kingdom